Ginkgo Bioworks, a company building a platform for cell programming and biosecurity, has successfully completed the gene therapy collaboration with Biogen announced in May 2021. The companies aimed to advance the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors. The collaboration achieved its goals of enhancing the AAV production titers of Biogen’s gene therapy manufacturing processes.
“We’re proud to work with industry-defining partners like Biogen to help global leaders in the biopharmaceutical industry redefine what’s possible in therapeutics discovery and manufacturing,” said Narendra Maheshri, VP Mammalian Engineering at Ginkgo Bioworks. “Significant improvements like these are the result of a platform-based approach to biological R&D. They are possible because our program leads work closely with our collaboration partners to take full advantage of the broad scale and deep sophistication of our highly-automated foundry and growing codebase.”
Check out our AAV CDMO service to expedite your gene therapy research
Related News
NeuExcell’s NXL-004 Secures FDA Orphan Drug Designation for Glioma Treatment
On December 7, 2023, Beijing time, NeuExcell Therapeutics announced that its proprietary AAV gene therapy product, NXL-004, designed for treating malignant glioma, has been awarded Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This...
PackGene Biotech Receives Exclusive C+ Round Investment from SDIC Fund, and Hosts a CGT Industry Salon to Discuss Global Strategies
December 1, 2023, PackGene Biotech, a frontrunner in gene therapy delivery, has successfully closed a landmark C+ funding round, securing over 100 million RMB exclusively from SDIC Fund Management Co., Ltd. This funding, a remarkable accomplishment in the current...
Tauopathy’s Role in Aβ Oligomer Formation: New Insights from Transgenic Primate Models on Alzheimer’s Pathogenesis
Tauopathy, characterized by protein tau and Aβ oligomer accumulation, is a significant aspect of Alzheimer's disease. The causal relationship between these accumulations and neurodegeneration remains unclear despite their links to various cognitive and movement...
Targeted Lysosomal Degradation of Mutant Huntingtin by Engineered Intrabody Peptide SM3
Huntington's disease (HD) is a devastating neurodegenerative condition caused by a mutation in the Huntingtin gene (HTT). This leads to the production of a mutant form of the huntingtin protein (mHTT) with an extended polyglutamine (polyQ) repeat, which has a...
Related Services
Plasmid CDMO Services
We provide high quality plasmids that are ideal for any phase of the drug development cycle.
READ MORE
AAV cGMP Manufacturing
READ MORE
AAV Capsid Engineering
Proven technology paving your path to effective therapies for cancer or genetic disorder
READ MORE
